Dr. Granville provides insight, guidance, and a collaborative approach to build DIA’s thought leadership, research and content strategy to support innovation and building efficiency in drug, device and diagnostics development. She brings 2 decades of regulatory science-related research experience to her role at DIA. Her research career focused on developing data to support regulatory decision making in the fields of tobacco regulatory science, preclinical and molecular toxicology, nonclinical drug development, and public health. She holds a BS in Biology from Yale University, an MSPH in Environmental Health from UNC Chapel Hill and a PhD in Biochemistry and Molecular Genetics from George Washington University.

Teresa Lamantia is Sr. Vice President, Operational Transformation and Performance at IQVIA, the world’s largest CRO and healthcare data science company. In this role she oversees the metrics and reporting team as well as the lifecycle transition management team for research and development solutions. She also serves as the global head of the COVID-19 Task Force. Prior to taking this role she serves as the head of Global Quality and Transformation, for Q2 Solutions, IQVIA laboratories, established in 2016. In this role she oversaw global quality assurance and transformation activities including continuous improvement, operational excellence, and integration/transformation strategic deliverables.

Bettina Ryll, MD/PhD founded the Melanoma Patient Network Europe in 2013 and developed a special interest in patient-centric clinical research and drug development. Bettina’s current areas of focus are Adaptive Licensing/ MAPPS , innovative sustainable healthcare models and patient-centered risk/ benefit assessment tools. She lectures and advises on patient-centric drug development, member of ASCO and ISPOR and current chair of the ESMO Patient Advocacy Working Group.

Anna graduated from Kharkiv National Medical University. She has a PhD, Master of Medical Sciences, is an Associate Professor and works as a cardiologist and researcher at the Kharkiv Medical Academy of Postgraduate Education. She has an MBA and a master’s degree in pedagogy, completed an internship at Harvard and Yale Universities, and is a qualified International lecturer and senior researcher. In 2014, she started her career in the clinical research industry. In March 2020, Anna opened the Pratia Ukraine LLC and SMO clinical research site, Pratia Clinic Ukraine, part of the international site network Pratia under the umbrella of the NEUCA group. Her company works with 10 medical institutions in 3 Ukrainian regions in clinical trials.